Membrane-type 4 matrix metalloproteinase (MT4-MMP) induces lung metastasis by alteration of primary breast tumour vascular architecture

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 9 B, 2009, Pages 4002-4013

  Chabottaux, Vincent ^a   Ricaud, Stéphanie ^b,c   Host, Laurent ^a   Blacher, Silvia ^a   Paye, Alexandra ^a   Thiry, Marc ^a   Garofalakis, Anikitos ^b,c   Pestourie, Carine ^b,c   Gombert, Karine ^c   Bruyere, Françoise ^a   Lewandowsky, Daniel ^d   Tavitian, Bertrand ^b,c   Foidart, Jean Michel ^a,e   Duconge, Frédéric ^b,c   Noel, Agnès ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^c INSERM   (France)

^d INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^e UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Angiogenesis; Breast cancer; Metastasis; MT MMP; Vessel architecture

Indexed keywords

MATRIX METALLOPROTEINASE 17;

ANIMAL; ARTICLE; BREAST TUMOR; CANCER TRANSPLANTATION; ENZYMOLOGY; EXPERIMENTAL NEOPLASM; FLUORESCENCE MICROSCOPY; HUMAN; LUNG TUMOR; LYMPH NODE METASTASIS; METABOLISM; METASTASIS; METHODOLOGY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PERICYTE; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MAMMARY NEOPLASMS, ANIMAL; MATRIX METALLOPROTEINASE 17; MICE; MICE, NUDE; MICROSCOPY, ELECTRON, TRANSMISSION; MICROSCOPY, FLUORESCENCE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES;

EID: 72949089968     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00764.x     Document Type: Article

References (50)

1. Cady B. Regional lymph node metastases; a singular manifestation of the process of clinical metastases in cancer: contemporary animal research and clinical reports suggest unifying concepts. Ann. Surg. Oncol. 2007, 14:1790-1800.
2. Folgueras AR, Pendas AM, Sanchez LM. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int. J Dev. Biol. 2004, 48:411-24.
3. Cauwe B, Van den Steen PE, Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol. 2007, 42:113-85.
4. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002, 2:161-74.
5. Chabottaux V, Noel A. Breast cancer progression: insights into multifaceted matrix metalloproteinases. Clin. Exp. Metastasis. 2007, 24:647-56.
6. Chabottaux V, Noel A. Matrix metalloproteinases to predict breast cancer metastases. Clin. Lab. Int. 2007, 31:8-10.
7. Handsley MM, Edwards DR. Metalloproteinases and their inhibitors in tumor angiogenesis. Int. J. Cancer. 2005, 115:849-60.
8. van Hinsbergh VW, Koolwijk P. Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc. Res. 2008, 78:203-12.
9. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006, 25:9-34.
10. Sounni NE, Noel A. Membrane type-matrix metalloproteinases and tumor progression. Biochimie. 2005, 87:329-42.
11. Sohail A, Sun Q, Zhao H. MT4-(MMP17) and MT6-MMP (MMP25), A unique set of membrane-anchored matrix metalloproteinases: properties and expression in cancer. Cancer Metastasis Rev. 2008, 27:289-302.
12. Puente XS, Pendas AM, Llano E. Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res. 1996, 56:944-9.
13. Kajita M, Kinoh H, Ito N. Human membrane type-4 matrix metalloproteinase (MT4-MMP) is encoded by a novel major transcript: isolation of complementary DNA clones for human and mouse mt4-mmp transcripts. FEBS Lett. 1999, 457:353-6.
14. Rikimaru A, Komori K, Sakamoto T. Establishment of an MT4-MMP-deficient mouse strain representing an efficient tracking system for MT4-MMP/MMP-17 expression in vivo using beta-galactosidase. Genes Cells. 2007, 12:1091-100.
15. Grant GM, Giambernardi TA, Grant AM. Overview of expression of matrix metalloproteinases (MMP-17, MMP-18, and MMP-20) in cultured human cells. Matrix Biol. 1999, 18:145-8.
16. Nuttall RK, Pennington CJ, Taplin J. Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Mol. Cancer Res. 2003, 1:333-45.
17. Riddick AC, Shukla CJ, Pennington CJ. Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br. J. Cancer. 2005, 92:2171-80.
18. Chabottaux V, Sounni NE, Pennington CJ. Membrane-type 4 matrix metalloproteinase promotes breast cancer growth and metastases. Cancer Res. 2006, 66:5165-72.
19. English WR, Puente XS, Freije JM. Membrane type 4 matrix metalloproteinase (MMP17) has tumor necrosis factor-alpha convertase activity but does not activate pro-MMP2. J. Biol. Chem. 2000, 275:14046-55.
20. Rozanov DV, Hahn-Dantona E, Strickland DK. The low density lipoprotein receptor-related protein LRP is regulated by membrane type-1 matrix metalloproteinase (MT1-MMP) proteolysis in malignant cells. J. Biol. Chem. 2004, 279:4260-8.
21. Gao G, Plaas A, Thompson VP. ADAMTS4 (aggrecanase-1) activation on the cell surface involves C-terminal cleavage by glycosylphosphatidyl inositol-anchored membrane type 4-matrix metalloproteinase and binding of the activated proteinase to chondroitin sulfate and heparan sulfate on syndecan-1. J. Biol. Chem. 2004, 279:10042-51.
22. Stewart MC, Fosang AJ, Bai Y. ADAMTS5-mediated aggrecanolysis in murine epiphyseal chondrocyte cultures. Osteoarthritis. Cartilage. 2006, 14:392-402.
23. Hashizume H, Baluk P, Morikawa S. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 2000, 156:1363-80.
24. Ballou B, Ernst LA, Andreko S. Sentinel lymph node imaging using quantum dots in mouse tumor models. Bioconjug. Chem. 2007, 18:389-96.
25. Morikawa S, Baluk P, Kaidoh T. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 2002, 160:985-1000.
26. Maeda H, Wu J, Sawa T. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control Release. 2000, 65:271-84.
27. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J. Drug Target. 2007, 15:457-64.
28. Chambers AF, Groom AC, MacDonald IC. Dissemintation and growth of cancer cells in metastatic sites. Nat. Rev. Cancer. 2002, 2:563-72.
29. Kim J, Yu W, Kovalski K. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell. 1998, 94:353-62.
30. Adachi Y, Yamamoto H, Itoh F. Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut. 1999, 45:252-8.
31. Montel V, Kleeman J, Agarwal D. Altered metastatic behavior of human breast cancer cells after experimental manipulation of matrix metalloproteinase 8 gene expression. Cancer Research. 2004, 64:1687-94.
32. Cao J, Chiarelli C, Kozarekar P. Membrane type 1-matrix metalloproteinase promotes human prostate cancer invasion and metastasis. Thromb. Haemost. 2005, 93:770-8.
33. Wyckoff JB, Jones JG, Condeelis JS. A critical step in metastasis: in vivo analysis of intravasation at the primary tumor. Cancer Res. 2000, 60:2504-11.
34. Koop S, Schmidt EE, MacDonald IC. Independence of metastatic ability and extravasation: metastatic ras-transformed and control fibroblasts extravasate equally well. Proc. Natl. Acad. Sci. USA. 1996, 93:11080-4.
35. Xian X, Hakansson J, Stahlberg A. Pericytes limit tumor cell metastasis. J. Clin. Invest. 2006, 116:642-51.
36. Gerhardt H, Semb H. Pericytes: gatekeepers in tumour cell metastasis. J. Mol. Med. 2008, 86:135-44.
37. Taniguchi S, Takeoka M, Ehara T. Structural fragility of blood vessels and peritoneum in calponin h1-deficient mice, resulting in an increase in hematogenous metastasis and peritoneal dissemination of malignant tumor cells. Cancer Res. 2001, 61:7627-34.
38. Plaisier M, Kapiteijn K, Koolwijk P. Involvement of membrane-type matrix metalloproteinases (MT-MMPs) in capillary tube formation by human endometrial microvascular endothelial cells: Role of MT3-MMP. J. Clin. Endocrinol. Metab. 2004, 89:5828-36.
39. Plaisier M, Koolwijk P, Hanemaaijer R. Membrane-type matrix metalloproteinases and vascularization in human endometrium during the menstrual cycle. Mol. Hum. Reprod. 2006, 12:11-8.
40. Rizki A, Weaver VM, Lee SY. A human breast cell model of preinvasive to invasive transition. Cancer Res. 2008, 68:1378-87.
41. Wang Y, Johnson AR, Ye QZ. Catalytic activities and substrate specificity of the human membrane type 4 matrix metalloproteinase catalytic domain. J. Biol. Chem. 1999, 274:33043-9.
42. Kolkenbrock H, Essers L, Ulbrich N. Biochemical characterization of the catalytic domain of membrane-type 4 matrix metalloproteinase. Biol. Chem. 1999, 380:1103-8.
43. Chantrain CF, Henriet P, Jodele S. Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases. Eur. J. Cancer. 2006, 42:310-8.
44. Jodele S, Chantrain CF, Blavier L. The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. Cancer Res. 2005, 65:3200-8.
45. Lehti K, Allen E, Birkedal-Hansen H. An MT1-MMP-PDGF receptor-beta axis regulates mural cell investment of the microvasculature. Genes Dev. 2005, 19:979-91.
46. Shofuda T, Shofuda K, Ferri N. Cleavage of focal adhesion kinase in vascular smooth muscle cells overexpressing membrane-type matrix metalloproteinases. Arterioscler. Thromb. Vasc. Biol. 2004, 24:839-44.
47. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ. Res. 2005, 97:512-23.
48. Chen J, Somanath PR, Razorenova O. Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat. Med. 2005, 11:1188-96.
49. Hawighorst T, Velasco P, Streit M. Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism. EMBO J. 2001, 20:2631-40.
50. Fears CY, Grammer JR, Stewart JE. Low-density lipoprotein receptor-related protein contributes to the antiangiogenic activity of thrombospondin-2 in a murine glioma model. Cancer Res. 2005, 65:9338-46.